MDM2 inhibition enhances GVL effects. Left, inhibition of MDM2 increases intracellular MDM2 and p53 in T cells, which leads to phenotypic and metabolic changes consistent with more activation and less inhibition, along with improved survival and enhanced cytotoxicity. Right, in AML, increased p53 leads to increased expression of MHC class I and class II molecules along with increased expression of TRAIL-R1/2, which together render the leukemia cells more susceptible to recognition and killing by T cells. Professional illustration by Somersault18:24.